BioSpace News Archive

The global Blood Glucose Monitoring Devices market size is expected to be worth around US$ 23.5 billion by 2030 from valued at US$ 12.70 billion in 2020 and is anticipated to grow at a CAGR of 7.10% from 2022 to 2030.

The global clinical laboratory services market size was valued at US$ 238 billion in 2021 and is expected to reach US$ 415 billion by 2030 with a CAGR of 6.5% from 2022 to 2030.

Global Medical Cyclotron market size is expected to be worth around US$ 384.3 million by 2030 from valued at US$ 218.2 million in 2020 and is anticipated to grow at a CAGR of 20.9 % during forecast period 2021 to 2030.

Lonza has reported sales of CHF 3 billion, growing 17.3% AER2 (16.8%1 CER) and CHF 987 million CORE EBITDA, resulting in a margin of 33.1%.

The global Point-of-Care Glucose Testing market size is expected to be worth around US$ 6,217.90 million by 2030 from valued at US$ 10.05 million in 2020 and is anticipated to grow at a CAGR of 3.85% from 2021 to 2030.

RemSleep Holdings Inc. announces the company has formally retained a new Senior Director for Regulatory Compliance and Regulatory submissions to gain FDA clearance to market the company’s medical device respiratory products.

Next Generation Immune Checkpoint Inhibitor TIM 3 Antibodies Will Be More Prominently Used As Combinational Cancer Therapy Says Kuick Research.

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical mid-stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and hepatocellular carcinoma (“HCC”), announced today that its 2022 annual meeting of stockholders (the “Annual Meeting”) has been further adjourned to Friday, August 5, 2022 at 9:00 a.m. Eastern Time.

IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2022 second quarter financial results before the market opens on Friday, July 29th.